The patient should be told that PRIFTIN may produce a reddish coloration of the urine, sweat, sputum, and tears, and the patient should be forewarned that contact lenses may be permanently stained. The patient should be advised that the reliability of oral or other systemic hormonal contraceptives may be affected; consideration should be given to using alternative contraceptive measures. For those patients with a propensity to nausea, vomiting, or gastrointestinal upset, administration of PRIFTIN with food may be useful. Patients should be instructed to notify their physician promptly of they experience any of the following: fever, loss of appetite, malaise, nausea and vomiting, darkened urine, yellowish discoloration of the skin and eyes, and pain or swelling of the joints.

Compliance with the full course of therapy must be emphasized, and the importance of not missing any doses of the daily administered companion medications in the Intensive Phase must be stressed. (See DOSAGE and ADMINISTRATION and WARNINGS).

Adults treated for tuberculosis with rifapentine should have baseline measurements of hepatic enzymes, bilirubin, a complete blood count, and a platelet count (or estimate).

Patients should be seen at least monthly during therapy and should be specifically questioned concerning symptoms associated with adverse reactions. All patients with abnormalities should have follow-up; including laboratory testing, if necessary. Routine laboratory monitoring for toxicity in people with normal baseline measurements is generally not necessary.

Therapeutic concentrations of rifampin have been shown to inhibit standard mocrobiological assays for serum folate and Vitamin B₁₂. Similar drug-laboratory interactions should be considered for rifapentine; thus. Alternative assay methods should be considered.

Please also see WARNINGS and PRECAUTIONS.

Bookmark this page: